Serum IFNα2 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort
Authors' conclusion
Serum IFNα2 levels measured by Simoa technology are associated with disease activity scores and characterize disease activity states in cSLE.
Study context
- Population
- Longitudinal cohort of childhood-onset SLE patients and healthy controls338 samples
- Participants
- 48 vs 67
- Exposure
- Serum IFNα2 levels (single-molecule array (Simoa)) vs IFN-I gene signature (IGS) as markers of disease activity
- cSLEn = 48
- Healthy controlsn = 67reference
- Outcome
- Association of serum IFNα2 levels and IGS with disease activity (SELENA-SLEDAI, BILAG-2004)
Methodological detailslinear mixed models, ROC analysis
- Linear mixed models
- ROC analysis
Main finding
As reported in the abstract
Association with disease activity
- Serum IFNα2 levels significantly associated with both cSELENA-SLEDAI and BILAG-2004 in the linear mixed model
- IGS did not show this association
- Both IFN-I assays characterised Low Lupus Disease Activity State (LLDAS) and disease flare in ROC analysis
Observational data: associations, not effects.
Further findings
Correlation between serum IFNα2 levels and IGS
- R
- 0.78
- P
- P < 0.0001
Change in mean baseline serum IFNα2 levels in cSLE · first 3 years after diagnosis
- Decrease
- 55.1%
- Δ
- 201 fg/ml
- P
- P < 0.001
- Mean value at 3 years
- 164 fg/ml
- Threshold discriminating patients from healthy controls
- 219.4 fg/ml
- IGS showed the same significant negative trend
Original publication
Serum IFNα2 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort. Rheumatology (Oxford). Published 14 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →